plerixafor (Mozobil®) accepted for use within NHSScotland
The SMC has accepted plerixafor in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged 1 year to <18 years with lymphoma or solid malignant tumours.
Source:
Scottish Medicines Consortium
SPS commentary:
The SMC has previously accepted plerixafor for the same indication, for use in adults.